ATE420084T1 - Neue imidazolderivate und deren verwendung als pharmazeutische mittel - Google Patents

Neue imidazolderivate und deren verwendung als pharmazeutische mittel

Info

Publication number
ATE420084T1
ATE420084T1 AT04765966T AT04765966T ATE420084T1 AT E420084 T1 ATE420084 T1 AT E420084T1 AT 04765966 T AT04765966 T AT 04765966T AT 04765966 T AT04765966 T AT 04765966T AT E420084 T1 ATE420084 T1 AT E420084T1
Authority
AT
Austria
Prior art keywords
pharmaceutical agents
imidazole derivatives
new imidazole
new
derivatives
Prior art date
Application number
AT04765966T
Other languages
English (en)
Inventor
Konrad Honold
Stefan Scheiblich
Hirschheydt Thomas Von
Edgar Voss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE420084T1 publication Critical patent/ATE420084T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04765966T 2003-10-17 2004-10-15 Neue imidazolderivate und deren verwendung als pharmazeutische mittel ATE420084T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03023677 2003-10-17

Publications (1)

Publication Number Publication Date
ATE420084T1 true ATE420084T1 (de) 2009-01-15

Family

ID=34486074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765966T ATE420084T1 (de) 2003-10-17 2004-10-15 Neue imidazolderivate und deren verwendung als pharmazeutische mittel

Country Status (16)

Country Link
US (1) US7169781B2 (de)
EP (1) EP1678163B1 (de)
JP (1) JP2007508344A (de)
KR (1) KR100796971B1 (de)
CN (1) CN1867563A (de)
AR (1) AR046286A1 (de)
AT (1) ATE420084T1 (de)
AU (1) AU2004283845A1 (de)
BR (1) BRPI0415525A (de)
CA (1) CA2538134A1 (de)
DE (1) DE602004018962D1 (de)
ES (1) ES2317030T3 (de)
MX (1) MXPA06003698A (de)
RU (1) RU2006116628A (de)
TW (1) TW200528447A (de)
WO (1) WO2005040154A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1889836T3 (pl) 2005-08-24 2013-10-31 Eisai R&D Man Co Ltd Nowa pochodna pirydyny i pochodna pirymidyny (3)
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2007149427A2 (en) * 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
CN101454311B (zh) 2006-08-23 2013-03-27 卫材R&D管理有限公司 苯氧基吡啶衍生物的盐和其结晶及其制备方法
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
CA2685876A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CN101687852A (zh) * 2007-05-24 2010-03-31 沃泰克斯药物股份有限公司 可用作激酶抑制剂的噻唑类和吡唑类化合物
MX2010003563A (es) * 2007-10-03 2010-06-02 Vertex Pharma Inhibidores de proteina cinasa de c-met.
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
MX393622B (es) 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションIncyte Corporation C−Met阻害剤としてのイミダゾ[1,2−b][1,2,4]トリアジン
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
JP6412503B2 (ja) 2012-11-21 2018-10-24 ピーティーシー セラピューティクス, インコーポレイテッド 置換逆ピリミジンBmi−1阻害剤
KR102232595B1 (ko) 2013-08-30 2021-03-26 피티씨 테라퓨틱스, 인크. 치환된 피리미딘 bmi-1 저해제
EP3071553A4 (de) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituierte pyridin- und pyrazin-bmi-1-hemmer
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス, インコーポレイテッド 膵臓癌を治療する方法
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
WO1996018626A1 (en) 1994-12-13 1996-06-20 F. Hoffmann-La Roche Ag Imidazole derivatives as protein kinase inhibitors in particular egf-r tyrosine kinase
WO1998057966A1 (en) * 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles

Also Published As

Publication number Publication date
CA2538134A1 (en) 2005-05-06
MXPA06003698A (es) 2006-06-05
ES2317030T3 (es) 2009-04-16
US7169781B2 (en) 2007-01-30
WO2005040154A1 (en) 2005-05-06
KR20060063985A (ko) 2006-06-12
TW200528447A (en) 2005-09-01
DE602004018962D1 (de) 2009-02-26
AU2004283845A1 (en) 2005-05-06
BRPI0415525A (pt) 2006-12-26
JP2007508344A (ja) 2007-04-05
US20050113342A1 (en) 2005-05-26
CN1867563A (zh) 2006-11-22
EP1678163A1 (de) 2006-07-12
RU2006116628A (ru) 2007-11-27
AR046286A1 (es) 2005-11-30
KR100796971B1 (ko) 2008-01-22
EP1678163B1 (de) 2009-01-07

Similar Documents

Publication Publication Date Title
DE602004018962D1 (de) Neue imidazolderivate und deren verwendung als pharmazeutische mittel
DE602005013491D1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
ATE378338T1 (de) Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE529420T1 (de) 3-ä(2-ää4-hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester-methansulfonat-hemihydrat und dessen verwendung als arzneimittel
DE60315892D1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60321043D1 (de) Biphenylderivate und deren verwendung als fungizide
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE602005022116D1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
DE502005006424D1 (de) Neue alkyl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
ATE399542T1 (de) Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE602004010284D1 (de) Aminochinolinderivate und deren verwendung als adenosin-a3-liganden
DE602004015600D1 (de) Neue imidazolderivative, deren herstellung und deren verwendung als medikament
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
ATE538125T1 (de) Neue 2-azaindol-derivate, deren herstellung und pharmazeutische verwendung als kinase-inhibitoren
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE60311277D1 (de) Benzotriazabicyclische derivate und deren verwendung als beta-lactamaseinhibitoren und antibakterielle mittel
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1678163

Country of ref document: EP

REN Ceased due to non-payment of the annual fee